Eur Rev Med Pharmacol Sci 2010; 14 (4): 407-414 Management of bone metastases M. Cappuccio, S. Bandiera, L. Babbi, L. Boriani, A. Corghi, L. Amendola, S. Colangeli, S. Terzi, A. Gasbarrini
Eur Rev Med Pharmacol Sci 2010; 14 (4): 395-406 Pancreatic cystic tumours: when to resect, when to observe R. Salvia, S. Crippa, S. Partelli, G. Malleo, G. Marcheggiani, M. Bacchion, G. Butturini, C. Bassi
Eur Rev Med Pharmacol Sci 2010; 14 (4): 386-394 Chemotherapy in pancreatic adenocarcinoma M. Squadroni, N. Fazio
Eur Rev Med Pharmacol Sci 2010; 14 (4): 375-385 Pancreatic cancer: diagnosis and endoscopic staging D. Galasso, A. Carnuccio, A. Larghi
Eur Rev Med Pharmacol Sci 2010; 14 (4): 371-374 Chemotherapy in biliary tract cancer G. Tonini, M.E. Fratto, B. Vincenzi, D. Santini
Eur Rev Med Pharmacol Sci 2010; 14 (4): 368-370 Liver resections for hilar cholangiocarcinoma F. Giuliante, F. Ardito, M. Vellone, G. Nuzzo
Eur Rev Med Pharmacol Sci 2010; 14 (4): 363-367 Cholangiocarcinoma: risk factors and clinical presentation M. Gatto, D. Alvaro
Eur Rev Med Pharmacol Sci 2010; 14 (4): 356-362 Transarterial chemoembolization (TACE) for unresectable HCC: A new life begins? M. Biolato*, G. Marrone*, S. Racco*, C. Di Stasi**, L. Miele*, G. Gasbarrini*, R. Landolfi*, A. Grieco*
Eur Rev Med Pharmacol Sci 2010; 14 (4): 352-355 Epidemiology, risk factors and surveillance of hepatocellular carcinoma G. Cabibbo 1,2 A. Craxì 1
Eur Rev Med Pharmacol Sci 2010; 14 (4): 347-351 Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues L. Bodei, G. Pepe, G. Paganelli
Eur Rev Med Pharmacol Sci 2010; 14 (4): 342-346 New biological agents for the treatment of the “high risk” IBD patients L. Guidi, M. Marzo, C. Felice, G. Mocci, L. Sparano, D. Pugliese, I. De Vitis, A. Papa, A. Armuzzi
Eur Rev Med Pharmacol Sci 2010; 14 (4): 334-341 The role of multimodality treatment in M0 rectal cancer: evidence and research V. Valentini, M.C. Barba, M.A. Gambacorta
Eur Rev Med Pharmacol Sci 2010; 14 (4): 327-333 Surgical treatment of small bowel neoplasms C. Coco, G. Rizzo, A. Manno, C. Mattana, A. Verbo
Eur Rev Med Pharmacol Sci 2010; 14 (4): 320-326 Small bowel nonendocrine neoplasms: current concepts and novel perspectives A.C. Piscaglia, M. Campanale, G. Gasbarrini
Eur Rev Med Pharmacol Sci 2010; 14 (4): 315-319 Surgical issues after neoadjuvant treatment for gastric cancer D. D’Ugo, R. Persiani, M. Zoccali, F. Cananzi, V. Vigorita, P. Mazzeo, A. Tufo, A. Biondi
Eur Rev Med Pharmacol Sci 2010; 14 (4): 309-314 Chemotherapy for locally advanced and metastatic gastric cancer: state of the art and future perspectives A. Bittoni, E. Maccaroni, M. Scartozzi, R. Berardi, S. Cascinu
Eur Rev Med Pharmacol Sci 2010; 14 (4): 302-308 Risk factors in gastric cancer D. Compare, A. Rocco, G. Nardone
Eur Rev Med Pharmacol Sci 2010; 14 (4): 292-301 Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia G. Mantovani
Eur Rev Med Pharmacol Sci 2010; 14 (4): 285-291 Chemoprophylaxis in gastrointestinal tumors M. Zilli, S. Iacobelli
Eur Rev Med Pharmacol Sci 2010; 14 (4): 272-276 Progress in endoscopic imaging of gastrointestinal tumors G. Costamagna, M. Marchese
